Table of Contents Author Guidelines Submit a Manuscript
International Journal of Pediatrics
Volume 2012, Article ID 843016, 11 pages
http://dx.doi.org/10.1155/2012/843016
Clinical Study

Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome

1Department of Pediatrics, RUSH University Medical Center, Chicago, IL 60612, USA
2Departments of Neurology and Biochemistry, RUSH University Medical Center, Chicago, IL 60612, USA

Received 12 December 2011; Revised 10 April 2012; Accepted 16 April 2012

Academic Editor: Sheffali Gulati

Copyright © 2012 Elizabeth Berry-Kravis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Turner, T. Webb, S. Wake, and H. Robinson, “Prevalence of fragile X syndrome,” American Journal of Medical Genetics, vol. 64, no. 1, pp. 196–197, 1996. View at Publisher · View at Google Scholar
  2. A. J. M. H. Verkerk, M. Pieretti, J. S. Sutcliffe et al., “Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome,” Cell, vol. 65, no. 5, pp. 905–914, 1991. View at Google Scholar · View at Scopus
  3. M. Pieretti, F. Zhang, Y. H. Fu et al., “Absence of expression of the FMR-1 gene in fragile X syndrome,” Cell, vol. 66, no. 4, pp. 817–822, 1991. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Devys, Y. Lutz, N. Rouyer, J. P. Bellocq, and J. L. Mandel, “The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation,” Nature Genetics, vol. 4, no. 4, pp. 335–340, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. R. J. Hagerman, “Physical and behavioral phenotype,” in Fragile X Syndrome: Diagnosis, Treatment, and Research, R. J. Hagerman and P. J. Hagerman, Eds., pp. 3–109, The Johns Hopkins University Press, Baltimore, Md, USA, 3rd edition, 2002. View at Google Scholar
  6. A. M. Lachiewicz, D. V. Dawson, and G. A. Spiridigliozzi, “Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males,” American Journal of Medical Genetics, vol. 92, no. 4, pp. 229–236, 2000. View at Publisher · View at Google Scholar
  7. R. J. Hagerman, K. Amiri, and A. Cronister, “Fragile X checklist,” American Journal of Medical Genetics, vol. 38, no. 2-3, pp. 283–287, 1991. View at Publisher · View at Google Scholar · View at Scopus
  8. A. M. Lachiewicz, G. A. Spiridigliozzi, C. M. Gullion, S. N. Ransford, and K. Rao, “Aberrant behaviors of young boys with fragile X syndrome,” American Journal on Mental Retardation, vol. 98, no. 5, pp. 567–579, 1994. View at Google Scholar · View at Scopus
  9. C. A. Erickson, J. E. Mullett, and C. J. McDougle, “Open-label memantine in fragile X syndrome,” Journal of Autism and Developmental Disorders, vol. 39, no. 12, pp. 1629–1635, 2009. View at Publisher · View at Google Scholar
  10. R. J. Hagerman, M. A. Murphy, and M. D. Wittenberger, “A controlled trial of stimulant medication in children with the fragile X syndrome,” American Journal of Medical Genetics, vol. 30, no. 1-2, pp. 377–392, 1988. View at Google Scholar · View at Scopus
  11. R. J. Hagerman, J. E. Riddle, L. S. Roberts, K. Breese, and M. Fulton, “Survey of the efficacy of clonidine in fragile X syndrome,” Developmental Brain Dysfunction, vol. 8, no. 4–6, pp. 336–344, 1995. View at Google Scholar · View at Scopus
  12. R. J. Hagerman, M. J. Fulton, A. Leaman, J. Riddle, K. Hagerman, and W. Sobesky, “A survey of fluoxetine therapy in fragile X syndrome,” Developmental Brain Dysfunction, vol. 7, no. 2-3, pp. 155–164, 1994. View at Google Scholar · View at Scopus
  13. E. Berry-Kravis, A. Sumis, C. Hervey et al., “Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome,” Journal of Developmental and Behavioral Pediatrics, vol. 29, no. 4, pp. 293–302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Paribello, L. Tao, A. Folino et al., “Open-label add-on treatment trial of minocycline in fragile X syndrome,” BMC Neurology, vol. 10, p. 91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Berry-Kravis, D. Hessl, S. Coffey et al., “A pilot open label, single dose trial of fenobam in adults with fragile X syndrome,” Journal of Medical Genetics, vol. 46, no. 4, pp. 266–271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Jacquemont, A. Curie, V. Des Portes et al., “Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056,” Science Translational Medicine, vol. 3, no. 64, Article ID 64ra1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Wang, R. Hagerman, B. Rathmell, P. Wang, and E. Berry-Kravis, “Arbaclofen treatment is associated with global behavioral improvement in fragileX syndrome (FXS): results of a randomized, controlledphase 2 trial,” in Proceedings of the 2010 Annual Meeting of the Society for Developmentaland Behavioral Pediatrics, Boston, Mass, USA, September 2010.
  18. R. N. Amaria, L. L. Billeisen, and R. J. Hagerman, “Medication use in fragile X syndrome,” Mental Health Aspects of Developmental Disabilities, vol. 4, pp. 143–147, 2001. View at Google Scholar
  19. E. Berry-Kravis, A. W. Grossman, L. S. Crnic, and W. T. Greenough, “Understanding fragile X syndrome,” Current Paediatrics, vol. 12, no. 4, pp. 316–324, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Berry-Kravis and K. Potanos, “Psychopharmacology in fragile X syndrome—present and future,” Mental Retardation and Developmental Disabilities Research Reviews, vol. 10, no. 1, pp. 42–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. C. A. Erickson, K. A. Stigler, L. K. Wink et al., “A prospective open-label study of aripiprazole in fragile X syndrome,” Psychopharmacology, vol. 216, no. 1, pp. 85–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. K. D. Wagner, P. Ambrosini, M. Rynn et al., “Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials,” Journal of the American Medical Association, vol. 290, no. 8, pp. 1033–1041, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. E. Roberts, D. B. Bailey, and M. L. Boccia, “Psychophysiological measures of arousal: documentation of treatment effects and impact of disability,” in Proceedings of the 8th International Fragile X Conference, Chicago, Ill, USA, 2002.
  24. R. J. Hagerman, L. J. Miller, J. McGrath-Clarke et al., “Influence of stimulants on electrodermal studies in fragile X syndrome,” Microscopy Research and Technique, vol. 57, no. 3, pp. 168–173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. G. Aman, R. E. Marks, S. H. Turbott, C. P. Wilsher, and S. N. Merry, “The clinical effects of methylphenidate and thioridazine in intellectually subaverage children: effects of cognitive motor preformance,” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 30, pp. 246–256, 1991. View at Google Scholar
  26. B. L. Handen, J. Janosky, and S. McAuliffe, “Long-term follow-up of children with mental retardation/borderline intellectual functioning and ADHD,” Journal of Abnormal Child Psychology, vol. 25, no. 4, pp. 287–295, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. R. J. Hagerman, J. Hills, S. Scharfenaker, and H. Lewis, “Fragile X syndrome and selective mutism,” American Journal of Medical Genetics, vol. 83, no. 4, pp. 313–317, 1999. View at Publisher · View at Google Scholar
  28. E. H. Cook Jr, R. Rowlett, C. Jaselskis, and B. L. Leventhal, “Fluoxetine treatment of children and adults with autistic disorder and mental retardation,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 31, no. 4, pp. 739–745, 1992. View at Google Scholar · View at Scopus
  29. C. J. McDougle, S. T. Naylor, D. J. Cohen, F. R. Volkmar, G. R. Heninger, and L. H. Price, “A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder,” Archives of General Psychiatry, vol. 53, no. 11, pp. 1001–1008, 1996. View at Google Scholar · View at Scopus
  30. J. Cohen, K. Kerr, T. Iacono et al., “Measuring emotion, behavior change and speech in individuals with fragile X syndrome whilst taking sertraline: a pilot of tools,” in Proceedings of the 8th International Fragile X Conference, Chicago, Ill, USA, 2002.
  31. D. K. Hilton, C. A. Martin, W. M. Heffron, B. D. Hall, and G. L. Johnson, “Imipramine treatment of ADHD in a fragile X child,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 30, no. 5, pp. 831–834, 1991. View at Google Scholar · View at Scopus
  32. J. K. Zubieta and N. E. Alessi, “Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children,” Journal of Clinical Psychopharmacology, vol. 12, no. 5, pp. 346–351, 1992. View at Google Scholar · View at Scopus
  33. J. T. McCracken, J. McGough, B. Shah et al., “Risperidone in children with autism and serious behavioral problems,” New England Journal of Medicine, vol. 347, no. 5, pp. 314–321, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Agarwal, P. Sitholey, S. Kumar, and M. Prasad, “Double-blind, placebo-controlled trial of clonidine in hyperactive children with mental retardation,” Mental Retardation, vol. 39, no. 4, pp. 259–267, 2001. View at Google Scholar
  35. S. Chang, S. M. Bray, Z. Li et al., “Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila,” Nature Chemical Biology, vol. 4, no. 4, pp. 256–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. F. Bear, “Therapeutic implications of the mGluR theory of fragile X mental retardation,” Genes, Brain and Behavior, vol. 4, no. 6, pp. 393–398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Berry-Kravis, A. Knox, and C. Hervey, “Targeted treatments for fragile X syndrome,” Journal of Neurodevelopmental Disorders, vol. 3, no. 3, pp. 193–210, 2011. View at Publisher · View at Google Scholar
  38. T. V. Bilousova, L. Dansie, M. Ngo et al., “Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model,” Journal of Medical Genetics, vol. 46, no. 2, pp. 94–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. C. A. Erickson, J. E. Mullett, and C. J. McDougle, “Brief report: acamprosate in fragile X syndrome,” Journal of Autism and Developmental Disorders, vol. 40, no. 11, pp. 1412–1416, 2010. View at Publisher · View at Google Scholar
  40. L. K. K. Pacey, S. P. Heximer, and D. R. Hampson, “Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures,” Molecular Pharmacology, vol. 76, no. 1, pp. 18–24, 2009. View at Publisher · View at Google Scholar · View at Scopus